NCT07623668PHASE3Recruiting
Privosegtor Investigation in Optic Neuropathies Efficacy Evaluation Research
Oculis
Start Date
5/28/2026
Completion Date
12/1/2028
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of privosegtor, a neuroprotective candidate, in patients diagnosed with optic neuritis (ON). Researchers will compare privosegtor and the standard of care (methylprednisolone) to a placebo and standard of care (methylprednisolone).
Eligibility Criteria
Age Range: 18 years to 50 years
Key Inclusion Criteria:
* Adult men and women (aged 18 to 50 years) with the first episode of ON in the study eye, associated with unilateral visual loss.
* Onset of visual loss symptoms in the previous 12 days before first administration of study treatment.
Key Exclusion Criteria:
\- Have a history or presence of any disorder or condition that may, in the opinion of the Investigator, likely interfere with the interpretation of the study results or participant safety
Interventions
DRUG
Privosegtor
DRUG
Methylprednisolone
OTHER
Placebo
Conditions
Optic Neuritis
Locations
Kahana Oculoplastic and Orbital Surgery
Livonia, Michigan 48152
United States
Neuro-Eye Clinical Trials
Houston, Texas 77074
United States